Lemont
Lemont
Lemont, Illinois, United States28 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-10-08 | NCT04108156 | |
| CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-10-02 | NCT07449923 | |
| A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products | Branch Vein Occlusion, Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, central retinal vein occlusion, diabetic macular edema, eye disorder, retinal disorder, retinal vein occlusion, thrombotic disease, vascular disorder | Active, not recruiting | Not stated | 2026-10-02 | NCT05476926 | |
| A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | Neovascular Age-related Macular Degeneration | Recruiting | Phase 4 | 2026-10-02 | NCT04853251 | |
| A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-30 | NCT06635148 | |
| A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-30 | NCT06571045 | |
| ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study | Eye Diseases, Hereditary, Geographic Atrophy, Skin Abnormalities, Skin and Connective Tissue Diseases, connective tissue disorder, eye disorder, macular degeneration, primary anetoderma, retinal degeneration, retinal disorder, skin disorder | Enrolling by invitation | Phase 2 | 2026-09-28 | NCT05481827 | |
| A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 | 2026-09-23 | NCT06557460 | |
| A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-22 | NCT07215234 | |
| A Study in Adults With Geographic Atrophy | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 | 2026-09-21 | NCT07606365 | |
| A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-09-18 | NCT06541704 | |
| A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-09-18 | NCT06491914 | |
| A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO | Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, eye disorder, retinal disorder, retinal vein occlusion, thrombotic disease, vascular disorder | Recruiting | Phase 2 | 2026-09-04 | NCT07205887 | |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | wet macular degeneration | Active, not recruiting | Phase 3 | 2026-09-03 | NCT06668064 | |
| Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration | Geographic Atrophy, age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Not applicable | 2026-08-26 | NCT06662162 | |
| A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-20 | NCT06957080 | |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) | Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Recruiting | Phase 2 / Phase 3 | 2026-08-06 | NCT07496567 | |
| Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), eye disorder, macular degeneration, nervous system disorder, retinal degeneration, retinal disorder, vision disorder | Recruiting | Phase 2 | 2026-08-05 | NCT07630649 | |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | Eye Diseases, Hereditary, Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-08-03 | NCT05407636 | |
| A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration | Neovascular Age-related Macular Degeneration (nAMD) | Active, not recruiting | Phase 4 | 2026-07-31 | NCT06795048 | |
| A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration | Neovascular Age-related Macular Degeneration | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-16 | NCT06660667 | |
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-06-01 | NCT06864988 | |
| A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | Geographic Atrophy, age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2026-05-14 | NCT06722157 | |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | Eye Diseases, Hereditary, Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Active, not recruiting | Phase 2 / Phase 3 | 2026-04-28 | NCT04704921 | |
| A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration | age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 1 | 2026-01-08 | NCT06825858 |